ArticleArchives of Razi Institute2024
Safety and Immunogenicity of Inactivated Fowl Adenovirus Serotype 8b Isolate Following Different Inactivation Time Intervals in Broiler Chickens.
Article in Archives of Razi Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, significant attention has been directed towards the development of inactivated fowl adenovirus (FAdV) vaccines within the poultry industry to combat outbreaks of inclusion body hepatitis (IBH). This study aimed to assess the safety and immunogenicity of an inactivated FAdV vaccine following different inactivation time intervals in commercial broiler chickens. The FAdV isolate UPM1137 was treated with binary ethyleneimine (BEI) at intervals of 20, 24, 28, 32, and 36 hours. All treated isolates underwent safety testing in specific pathogen-free (SPF) chicken embryonated eggs (CEE), followed by safety and immunogenicity trials in SPF chickens. The findings demonstrated that isolates treated at 20, 24, and 28 hours induced over 80% mortality in SPF CEE, while no mortality was observed in isolates treated at 32 and 36 hours. In SPF chickens, there were no clinical signs or gross and histological lesions recorded throughout the trial for those inoculated with isolates treated at 32 and 36 hours, indicating that these treatments rendered the virus completely inactivated and safe for use in commercial broiler chickens. Based on ELISA results, chickens vaccinated with the inactivated FAdV at 32 hours (group B) exhibited a higher antibody response compared to those vaccinated with the inactivated FAdV at 36 hours (group A) at days 14 and 28 post-inoculation (pi). At day 28 pi, the mean antibody titers for the booster groups in both group A and group B were significantly higher (p < 0.05) compared to the control group. These results indicate that both FAdV vaccines, using inactivated inocula at 32 and 36 hours, are safe and immunogenic in broiler chickens, particularly by day 28 pi following booster vaccination. Thus, it was concluded that the optimal duration for FAdV inactivation is 32 hours, making it highly suitable for future vaccine formulations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.